<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346177</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IND-11196-02</org_study_id>
    <nct_id>NCT00346177</nct_id>
  </id_info>
  <brief_title>Stem Cell Study for Patients With Heart Failure</brief_title>
  <official_title>Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF &lt; 40%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Losordo, Douglas, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Losordo, Douglas, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if cell therapy with your own cells (autologous
      cells) delivered with a catheter to regions of the heart with poor blood flow will be safe
      and if it will improve your ejection fraction and heart failure symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding not obtained. No subjects enrolled.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stem Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cells</intervention_name>
    <description>Intramyocardial injections</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects greater than 21 years old.

          -  Subjects with functional class (NYHA) III ischemic heart failure.

          -  Subjects who have attempted &quot;best&quot; cardiac medical therapy including long-acting
             nitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-converting
             enzyme inhibitors without control of symptoms.

          -  Subjects must be identified as non-candidates for conventional revascularization by
             their referring cardiologist. The patient's angiogram will then be reviewed by an
             independent interventional cardiologist and independent cardiac surgeon to determine
             if the patient is eligible for revascularization.

          -  Subjects must have left ventricular ejection fraction &lt;40% by echocardiography.

          -  All subjects must have a recent coronary angiogram (within the last 1 year) to
             document the coronary anatomy and insure the presence of coronary disease that is not
             amenable to standard revascularization procedures.

          -  Have serum B-type Natriuretic Peptide (BNP) level &gt;100 pg/ml.

        Exclusion Criteria:

          -  Myocardial infarction (Q wave or non-Q wave defined as CKMB &gt;3 times normal) within 30
             days of treatment.

          -  Successful coronary revascularization procedures within 3 months of study enrollment.

          -  Documented stroke or transient ischemic attack (TIA) within 60 days of study
             enrollment.

          -  NYHA Class I, II or IV heart failure and patients with idiopathic or non-ischemic
             heart failure.

          -  History of severe aortic stenosis (aortic valve area &lt; 1.0 cm2) or insufficiency
             (&gt;2+); severe mitral stenosis (mitral valve area &lt;1.5 cm2); or severe mitral
             insufficiency(&gt;2+).

          -  Implantation of biventricular pacemaker within 90 days of study treatment.

          -  Severe co-morbidity associated with a reduction in life expectancy of less than 1
             year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary
             disease, renal failure or cancer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas W. Losordo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Feinberg Cardiovascular Research Institute, Program in Cardiovascular Regenerative Medicine</name_title>
    <organization>Northwestern University/Northwestern Memorial Hospital</organization>
  </responsible_party>
  <keyword>heart</keyword>
  <keyword>stem Cells</keyword>
  <keyword>low EF</keyword>
  <keyword>heart attack</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>congestive heart failure</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Low Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

